HAIFA, Israel, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc . (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it will initiate Phase II clinical trials in the United States in the first week of September 2012 to evaluate the safety and efficacy of its PLacental Expanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). The U.S. Food and Drug Administration (FDA) had granted the Company clearance to start the Phase II clinical trial in April of this year.
Pluristem Commences U.S. FDA Phase II Clinical Trial For Intermittent Claudication
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts